New analyses and real-world evidence highlight outcomes with Altuvoct®, Elocta® and Alprolix® in haemophilia A and B

STOCKHOLM, June 30, 2026 /PRNewswire/ -- Sobi® today announced new data across its haemophilia portfolio will be presented at the 2026 Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Paris, from 11-15 July 2026. Presentations include new analyses and real-world evidence evaluating treatment outcomes with Altuvoct, Elocta and Alprolix in people living with haemophilia A and B.

The data being presented include oral and poster presentations evaluating joint health outcomes, bleeding outcomes, perioperative management and real-world treatment experience across multiple patient populations and clinical settings.

"People living with haemophilia continue to seek treatment approaches that can support long-term bleed protection, joint health and quality of life in everyday clinical practice," said Lydia Abad-Franch, MD, Chief Medical Officer at Sobi. "The breadth of data being presented at ISTH 2026 reflects our continued commitment to advancing care through both clinical development and real-world evidence generation to help improve outcomes for people living with haemophilia."


        
          Altuvoct(R)




        Joint Health in Patients with Severe Haemophilia A Treated with            Oral presentation
Efanesoctocog Alfa: 12-Month Interim Results from the FREEDOM              #OC 43.1
Study                                                                       Session: Comorbidities
                                                                            in
                                                                           haemophilia
                                                                           13 July 2026 at
                                                                            02:45 PM -03:00 PM
                                                                            CEST




        Joint Health Outcomes with Efanesoctocog Alfa Prophylaxis for              Poster presentation
Patients with Severe Haemophilia A: Third Interim Analysis of the          #PB3282
Phase 3 XTEND-ed Study                                                     14 July 2026 at 13:45 -
                                                                           14:45

        
          In collaboration with Sanofi



        REFINE study protocol: Real-World Outcomes of Efanesoctocog                Poster presentation
Alfa in Central and Eastern Europe Study Design                            #PB2164
                                                                           13 July 2026 at 13:45 -
                                                                           14:45



        Baseline Characteristics of Patients Switching to Prophylactic             Poster presentation
Efanesoctocog Alfa Therapy Evaluated for Joint Health in Haemophilia       #PB3293
A in Taiwan (PROTECT-ALT Study)                                            13 July 2026 at 13:45 -
                                                                           14:45

        
          In collaboration with Sanofi



        Retrospective, Real-World Study of Annual Bleeding Rate Changes            Poster presentation
Reported in the Microhealth Digital App by Patients with Haemophilia       #PB2106
A Transitioning to Efanesoctocog Alfa                                      13 July 2026 at 13:45 -
In collaboration with Sanofi                                               14:45




        
          Elocta(R)




        Interim Analysis of the A-MORE Real-World Atudy: 4-year Treatment          Poster presentation
Outcomes with a Recombinant Factor VIII Fc in the Overall and Non-         #PB3324
Severe Populations                                                         14 July 2026 at 13:45 -
                                                                           14:45



        
          Alprolix(R)




        Final Surgery Data from B-MORE: A 24-Month, Prospective, Non-              Poster presentation
Interventional Study of the Real-World Effectiveness and Usage of          # PB2117
rFIXFc in Haemophilia B                                                    13 July 2026 at 13:45 -
                                                                           14:45



        Perioperative Management of Haemophilia B: A HaemSTAR UK-Wide              Poster presentation
Audit                                                                      #PB3090
                                                                           14 July 2026 at 13:45 -
                                                                           14:45

About ALTUVOCT®

ALTUVOCT (efanesoctocog alfa) [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] (formerly BIVV001) is the first high-sustained FVIII replacement therapy with the potential to deliver near-normal factor activity levels for a significant part of the week, improving bleed protection in a once-weekly dose for people with haemophilia A. Efanesoctocog alfa builds on the established Fc fusion technology by innovatively adding a region of von Willebrand factor and XTEN® polypeptides to extend its time in circulation. It is the only therapy that has been shown to break through the von Willebrand factor ceiling, which imposes a half-life limitation on current factor VIII therapies. The European Commission granted Orphan Drug designation in June 2019. It is approved and marketed as ALTUVOCT™ by Sobi in Europe, Israel, Saudi Arabia, United Arab Emirates and Kuwait. It is approved and marketed as ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] by Sanofi in the United States, Japan and Taiwan.

About Elocta®/Eloctate®

Elocta®/Eloctate® (efmoroctocog alfa) is a recombinant clotting factor therapy developed for haemophilia A using Fc fusion technology to prolong circulation in the body. It is engineered by fusing factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Elocta to use a naturally occurring pathway to extend the time the therapy remains in the body (half-life). Elocta is manufactured using a human cell line in an environment free of animal and human additives. Elocta is approved and marketed by Sobi for the treatment of haemophilia A in the EU, the UK, Iceland, Kuwait, Liechtenstein, Norway, Bosnia & Herzegovina, Israel, North Macedonia, Oman, Serbia, Tunisia, Turkey, Saudi Arabia and Switzerland. It is approved and marketed as Eloctate® (Antihemophilic Factor [Recombinant], Fc Fusion Protein) by Sanofi in the United States, Canada Japan, Australia, New Zealand and other countries, where Sanofi has the marketing rights.

About Alprolix®

Alprolix® (eftrenonacog alfa) is a recombinant clotting factor therapy developed for haemophilia B using Fc fusion technology to prolong circulation in the body. It is engineered by fusing factor IX to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Alprolix to use a naturally occurring pathway to extend the time the therapy remains in the body (half-life). Alprolix is manufactured using a human cell line in an environment free of animal and human additives. Alprolix is approved and marketed by Sobi for the treatment of haemophilia B in the EU, the UK, Iceland, Kuwait, Liechtenstein, Norway, Saudi Arabia and Switzerland. It is also approved in the United States, Canada, Japan, Australia, New Zealand and other countries where Sanofi has the marketing rights.

About the Sanofi and Sobi collaboration

Sobi and Sanofi collaborate on the development and commercialisation of Alprolix® and Elocta®/Eloctate®. The companies also collaborate on the development and commercialisation of ALTUVOCT® (efanesoctocog alfa), or ALTUVIIIO™ in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory.

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Visiting address
Norra Stationsgatan 93A, Stockholm
+46 8 697 20 00
info@sobi.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-to-showcase-new-data-across-haemophilia-portfolio-at-isth-2026,c4368627

The following files are available for download:


 
 https://mb.cision.com/Main/14266/4368627/4171695.pdf Sobi to showcase new data across haemophilia portfolio
                                                          at ISTH 2026

View original content:https://www.prnewswire.co.uk/news-releases/sobi-to-showcase-new-data-across-haemophilia-portfolio-at-isth-2026-302814185.html

Tags

More Like This

Sobi to present new data at EAHAD 2024

Sobi will showcase extensive research and clinical outcomes at ISTH 2025

Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026

Sobi's strength in haematology to be showcased at ASH 2024

Sobi presents clinical data at WFH 2025 Comprehensive Care Summit

European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A

Sobi to present new data at ASH 2023 Annual Meeting

Sobi to present new clinical and real-world data at EHA 2026 in Stockholm